Latest & greatest articles for lansoprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lansoprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lansoprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lansoprazole

1. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis (Full text)

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO).In this phase III, double-blind, multicentre study, patients with endoscopically confirmed EO were randomised 1:1 to receive vonoprazan 20 mg or lansoprazole 30 mg, once daily for up (...) to 8 weeks. The primary endpoint was EO healing rate at 8 weeks. The secondary endpoints were EO healing rates at 2 and 4 weeks. Safety endpoints included treatment-emergent adverse events (TEAEs).In the vonoprazan (n=238) and lansoprazole (n=230) arms, 8-week EO healing rates were 92.4% and 91.3%, respectively (difference 1.1% (95% CI -3.822% to 6.087%)). The respective 2-week EO healing rates were 75.0% and 67.8% (difference 7.2% (95% CI -1.054% to 15.371%)), and the respective 4-week EO healing

2019 EvidenceUpdates PubMed

2. Lansoprazole

Lansoprazole Top results for lansoprazole - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lansoprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study (Full text)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use.A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter (...) , single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence. The patients received vonoprazan (10 mg or 20 mg) or lansoprazole 15 mg once daily. For DB, non-inferiority of the proportion of patients with recurrent PU within 24 weeks was analysed by Farrington and Manning test (significance level 2.5%, non-inferiority margin 8.3%; primary endpoint), recurrent PU within 12 weeks, bleeding and time-to-event of PU (secondary

2017 EvidenceUpdates PubMed

4. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy (PubMed)

Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy To evaluate the efficacy and tolerability of replacing tetracycline with amoxicillin in bismuth quadruple therapy.Subjects who were infected with Helicobacter pylori and naïve to treatment were randomly (1:1) assigned to receive a 14-day modified bismuth quadruple therapy: lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg (elemental bismuth), twice a day

2015 EvidenceUpdates

5. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. (Full text)

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. Asymptomatic gastroesophageal reflux (GER) is prevalent in children with asthma. Untreated GER has been postulated to be a cause of inadequate asthma control in children despite inhaled corticosteroid treatment, but it is not known whether treatment with proton pump inhibitors improves asthma control.To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER.The (...) Study of Acid Reflux in Children With Asthma, a randomized, masked, placebo-controlled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma control who were receiving inhaled corticosteroid treatment. Three hundred six participants enrolled from April 2007 to September 2010 at 19 US academic clinical centers were followed up for 24 weeks. A subgroup had an esophageal pH study before randomization.Participating children were randomly assigned to receive either

2012 JAMA PubMed

6. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients (PubMed)

A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).Twelve-month, randomized, observer-blind, controlled trial.A university hospital and three city hospitals in Miyagi prefecture in Japan.One hundred patients with COPD (mean age (...) +/- SD 74.9 +/- 8.2) participated. They were all ex-smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.Frequency of common colds and COPD exacerbations.The number of exacerbations per person

2009 EvidenceUpdates

7. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study

Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

8. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. (PubMed)

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain.We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H (...) . pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications.During a median follow-up of 12 months, 9 of the 61 patients in the placebo group (14.8 percent), as compared with 1 of the 62 patients in the lansoprazole group (1.6 percent), had a recurrence of ulcer complications (adjusted hazard ratio, 9.6; 95 percent

2002 NEJM

9. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

2001 DARE.

10. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, De Luca L Authors' objectives To assess the efficacy of lansoprazole in eradicating Helicobacter pylori and healing peptic ulcers. Searching The authors searched MEDLINE and also scanned (...) the bibliographies of articles for additional relevant studies (search terms not stated). Only full-text published articles (1993 to 1996) were included although five published abstracts were included for the triple- therapy comparison of lansoprazole versus another proton pump inhibitor (PPI). Only English language studies were included. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs). Specific interventions included in the review Comparisons of: 1

1998 DARE.

11. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview.

Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Efficacy of lansoprazole in the short-and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Manzionna G, Pace F, Bianchi Porro G Authors' objectives To re-evaluate the short- and long-term data regarding the treatment (...) of reflux oesophagitis with the newly developed proton-pump inhibitor lansoprazole, compared with other acid suppressant drugs. Searching The literature was searched both manually and electronically (MEDLINE). Only articles published in the English language between 1991 and 1996 were considered. Study selection Study designs of evaluations included in the review Randomised, controlled clinical studies were included. Specific interventions included in the review Lansoprazole (15, 30 or 60 mg/day

1997 DARE.

12. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis Tunis S R, Sheinhait I A, Schmid C H, Bishop D J, Ross S D Authors' objectives To compare the gastric ulcer healing rates of lansoprazole with histamine2-receptor antagonists (H2RAs). Searching (...) MEDLINE (1966 - 16 January 1996) including all languages, using the subject heading 'stomach ulcer' and text terms 'lansoprazole', 'lanzor', 'ogast', 'takepron', 'Prevacid', 'AG-1749', and 'EN-123065'. In addition, Current Contents was searched weekly, and bibliographies were handsearched. Unpublished trials were obtained from the drug's manufacturer. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing lansoprazole with a H2RA, recruiting

1997 DARE.

13. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Poynard T, Lemaire M, Agostini H Authors' objectives To compare the clinical efficacy (...) of lansoprazole with the efficacies of ranitidine and famotidine. Searching The trials were identified using a MEDLINE search, a review of gastroenterology journals and from the files of two pharmaceutical companies (Houde and Takeda). Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Lansoprazole at the usual dose of 30 mg compared with famotidine (4 0mg) or ranitidine (300 mg). Participants

1995 DARE.